1
|
Zeh N, Schmidt M, Schulz P, Fischer S. The new frontier in CHO cell line development: From random to targeted transgene integration technologies. Biotechnol Adv 2024; 75:108402. [PMID: 38950872 DOI: 10.1016/j.biotechadv.2024.108402] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2024] [Revised: 06/21/2024] [Accepted: 06/27/2024] [Indexed: 07/03/2024]
Abstract
Cell line development represents a crucial step in the development process of a therapeutic glycoprotein. Chinese hamster ovary (CHO) cells are the most frequently employed mammalian host cell system for the industrial manufacturing of biologics. The predominant application of CHO cells for heterologous recombinant protein expression lies in the relative simplicity of stably introducing ectopic DNA into the CHO host cell genome. Since CHO cells were first used as expression host for the industrial production of biologics in the late 1980s, stable genomic transgene integration has been achieved almost exclusively by random integration. Since then, random transgene integration had become the gold standard for generating stable CHO production cell lines due to a lack of viable alternatives. However, it was eventually demonstrated that this approach poses significant challenges on the cell line development process such as an increased risk of inducing cell line instability. In recent years, significant discoveries of new and highly potent (semi)-targeted transgene integration systems have paved the way for a technological revolution in the cell line development sector. These advanced methodologies comprise the application of transposase-, recombinase- or Cas9 nuclease-mediated site-specific genomic integration techniques, which enable a scarless transfer of the transgene expression cassette into transcriptionally active loci within the host cell genome. This review summarizes recent advancements in the field of transgene integration technologies for CHO cell line development and compare them to the established random integration approach. Moreover, advantages and limitations of (semi)-targeted integration techniques are discussed, and benefits and opportunities for the biopharmaceutical industry are outlined.
Collapse
Affiliation(s)
- Nikolas Zeh
- Cell Line Development, Bioprocess Development Biologicals, Boehringer Ingelheim Pharma GmbH and Co.KG, Biberach an der Riss, Germany
| | - Moritz Schmidt
- Cell Line Development, Bioprocess Development Biologicals, Boehringer Ingelheim Pharma GmbH and Co.KG, Biberach an der Riss, Germany
| | - Patrick Schulz
- Cell Line Development, Bioprocess Development Biologicals, Boehringer Ingelheim Pharma GmbH and Co.KG, Biberach an der Riss, Germany
| | - Simon Fischer
- Cell Line Development, Bioprocess Development Biologicals, Boehringer Ingelheim Pharma GmbH and Co.KG, Biberach an der Riss, Germany.
| |
Collapse
|
2
|
Chakrabarti L, Savery J, Mpindi JP, Klover J, Li L, Zhu J. Simplifying stable CHO cell line generation with high probability of monoclonality by using microfluidic dispensing as an alternative to fluorescence activated cell sorting. Biotechnol Prog 2024; 40:e3441. [PMID: 38462762 DOI: 10.1002/btpr.3441] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2023] [Revised: 01/27/2024] [Accepted: 01/30/2024] [Indexed: 03/12/2024]
Abstract
Single cell cloning is a critical step for cell line development (CLD) for therapeutic protein production, with proof of monoclonality being compulsorily sought in regulatory filings. Among the different single cell deposition technologies, we found that fluorescence activated cell sorting (FACS) offers high probability of monoclonality and can allow selective enrichment of the producer cells. However, FACS instruments are expensive and resource-intensive, have a large footprint, require highly skilled operators and take hours for setup, thereby complicating the cell line generation process. With the aim of finding an easy-to-use alternative to FACS, we identified a flow cytometry-based microfluidic cell dispenser, which presents a single cell sorting solution for biopharmaceutical CLD. The microfluidic cell dispenser is small, budget-friendly, easy-to-use, requires lower-cost consumables, permits flow cytometry-enabled multiparametric target cell enrichment and offers fast and gentle single cell dispensing into multiwell plates. Following comprehensive evaluation, we found that single cell deposition by the microfluidic cell dispenser resulted in >99% probability of monoclonality for production cell lines. Moreover, the clonally derived producer cell lines generated from the microfluidic cell dispenser demonstrated comparable or improved growth profiles and production capability compared to the FACS derived cell lines. Taken together, microfluidic cell dispensing can serve as a cost-effective, efficient and convenient alternative to FACS, simplifying the biopharmaceutical CLD platform with significant reductions in both scientist time and running costs.
Collapse
Affiliation(s)
- Lina Chakrabarti
- Cell Culture & Fermentation Sciences, BioPharmaceuticals Development, R&D, AstraZeneca, Gaithersburg, USA
| | - James Savery
- Machine Learning & AI, BioPharmaceuticals Development, R&D, AstraZeneca, Cambridge, UK
| | - John Patrick Mpindi
- Biostatistics, BioPharmaceuticals Development, R&D, AstraZeneca, Cambridge, UK
| | - Judith Klover
- Cell Culture & Fermentation Sciences, BioPharmaceuticals Development, R&D, AstraZeneca, Gaithersburg, USA
| | - Lina Li
- Cell Culture & Fermentation Sciences, BioPharmaceuticals Development, R&D, AstraZeneca, Gaithersburg, USA
| | - Jie Zhu
- Cell Culture & Fermentation Sciences, BioPharmaceuticals Development, R&D, AstraZeneca, Gaithersburg, USA
| |
Collapse
|
3
|
Roshani A, Mohammadi M, Bahadori T, Ahmadi Zare H, Judaki MA, Mobini M, Golsaz-Shirazi F, Jeddi-Tehrani M, Amiri MM, Shokri F. Comparison of different transient gene expression systems for the production of a new humanized anti-HER2 monoclonal antibody (Hersintuzumab). Daru 2023; 31:221-231. [PMID: 37695454 PMCID: PMC10624790 DOI: 10.1007/s40199-023-00477-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2023] [Accepted: 08/05/2023] [Indexed: 09/12/2023] Open
Abstract
BACKGROUND Producing therapeutic proteins can be done quickly and on a large scale through Transient Gene Expression (TGE). Chinese hamster ovary (CHO) cell lines are commonly used to achieve this. Although there are few comparative studies, TGE has been observed in suspension-adapted CHO cells. OBJECTIVES We tested TGE's effectiveness in DG-44, CHO-S, and ExpiCHO-S cell lines with four transfection reagents. METHODS A design of experiments (DoE) was followed to optimize transfection using a recombinant monoclonal antibody (mAb) construct. To evaluate the efficacy, flow cytometry and ELISA were used. Feeding strategies and temperature shifts were implemented to enhance transfection effectiveness. The quality of the mAb was assessed through ELISA, SDS-PAGE, and proliferation inhibition assays. RESULTS We adapted all cell lines to grow in suspension using a serum-free medium. Our findings from flow cytometry and ELISA tests indicate that PEI and Pmax reagents had a higher rate of transfection and mAb production than the ExpiCHO commercial transfection reagent. While DG-44 cells had better transfection efficiency than CHO-S and ExpiCHO-S, there was no significant difference between CHO-S and ExpiCHO-S. Our TGE system was more productive at 32 °C than at 37 °C. In the optimized TGE of Pmax-based transfection in DG-44 at 37 and 32 °C, the production level of mAb was more than half of the amount of the commercial ExpiCHO-S expression system. Still, the number of transfected cells was three times higher, making it more efficient. The purified mAb from all transfected cell lines had similar structural and functional properties under different conditions. CONCLUSION Our research shows that using Pmax and DG-44 cells in the TGE system is a cost-effective and efficient way to produce humanized monoclonal antibodies. We discovered that this method outperforms the ExpiCHO-S kit.
Collapse
Affiliation(s)
- Ali Roshani
- Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
| | - Mehdi Mohammadi
- Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
| | - Tannaz Bahadori
- Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
| | - Hengameh Ahmadi Zare
- Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
| | - Mohammad Ali Judaki
- Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
| | - Maryam Mobini
- Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
| | - Forough Golsaz-Shirazi
- Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
| | - Mahmood Jeddi-Tehrani
- Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran.
| | - Mohammad Mehdi Amiri
- Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
| | - Fazel Shokri
- Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
| |
Collapse
|
4
|
Listek M, Hönow A, Gossen M, Hanack K. Comment on "Monoclonal Antibody Discovery Based on Precise Selection of Single Transgenic Hybridomas with an On-Cell-Surface and Antigen-Specific Anchor". ACS APPLIED MATERIALS & INTERFACES 2023; 15:43219-43222. [PMID: 37676755 DOI: 10.1021/acsami.3c05317] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 09/09/2023]
Abstract
In the original paper, Li and co-workers [ACS Appl. Mater. Interfaces 2022, 14, 17128-17141] described their approach to select specific hybridoma cells from a polyclonal hybridoma pool by using a cell surface anchor to catch the secreted antibody. The antigen-specific detection was performed with streptavidin-labeled antigen and a PE-labeled anti-F(ab')2 antibody. The present comment offers a clearer description of the selection system originally published by Listek et al. in 2020 and provides further information about the importance of controls and recent adaptations made by our lab.
Collapse
Affiliation(s)
- Martin Listek
- Immunotechnology Group, Institute of Biochemistry and Biology, University of Potsdam, 14469 Potsdam, Germany
| | - Anja Hönow
- Immunotechnology Group, Institute of Biochemistry and Biology, University of Potsdam, 14469 Potsdam, Germany
- new/era/mabs GmbH, August-Bebel-Str. 89, 14482 Potsdam, Germany
| | - Manfred Gossen
- Berlin-Brandenburg Center for Regenerative Therapies (BCRT), 13353 Berlin, Germany
- Helmholtz-Zentrum Geesthacht, Institute of Active Polymers, 14513 Teltow, Germany
| | - Katja Hanack
- Immunotechnology Group, Institute of Biochemistry and Biology, University of Potsdam, 14469 Potsdam, Germany
- new/era/mabs GmbH, August-Bebel-Str. 89, 14482 Potsdam, Germany
| |
Collapse
|
5
|
Gätjen D, Wieczorek M, Listek M, Tomszak F, Nölle V, Hanack K, Droste M. A switchable secrete-and-capture system enables efficient selection of Pichia pastoris clones producing high yields of Fab fragments. J Immunol Methods 2022; 511:113383. [PMID: 36356896 DOI: 10.1016/j.jim.2022.113383] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2022] [Revised: 11/03/2022] [Accepted: 11/03/2022] [Indexed: 11/09/2022]
Abstract
Pichia pastoris (syn. Komagataella phaffii) represents a commonly used expression system in the biotech industry. High clonal variation of transformants, however, typically results in a broad range of specific productivities for secreted proteins. To isolate rare clones with exceedingly high product titers, an extensive number of clones need to be screened. In contrast to high-throughput screenings of P. pastoris clones in microtiter plates, secrete-and-capture methodologies have the potential to efficiently isolate high-producer clones among millions of cells through fluorescence-activated cell sorting (FACS). Here, we describe a novel approach for the non-covalent binding of fragment antigen-binding (Fab) proteins to the cell surface for the isolation of high-producing clones. Eight different single-chain variable fragment (scFv)-based capture matrices specific for the constant part of the Fabs were fused to the Saccharomyces cerevisiae alpha-agglutinin (SAG1) anchor protein for surface display in P. pastoris. By encoding the capture matrix on an episomal plasmid harboring inherently unstable autonomously replicating sequences (ARS), this secrete-and-capture system offers a switchable scFv display. Efficient plasmid clearance upon removal of selective pressure enabled the direct use of isolated clones for subsequent Fab production. Flow-sorted clones (n = 276) displaying high amounts of Fabs showed a significant increase in median Fab titers detected in the cell-free supernatant (CFS) compared to unsorted clones (n = 276) when cells were cultivated in microtiter plates (factor in the range of ∼21-49). Fab titers of clones exhibiting the highest product titer observed for each of the two approaches were increased by up to 8-fold for the sorted clone. Improved Fab yields of sorted cells vs. unsorted cells were confirmed in an upscaled shake flask cultivation of selected candidates (factor in the range of ∼2-3). Hence, the developed display-based selection method proved to be a valuable tool for efficient clone screening in the early stages of our bioprocess development.
Collapse
Affiliation(s)
- Dominic Gätjen
- Miltenyi Biotec B.V. & Co. KG, Friedrich-Ebert-Straße 68, 51429 Bergisch Gladbach, Germany; Institute of Biochemistry and Biology, University of Potsdam, Karl-Liebknecht-Straße 24-25, 14476 Potsdam, Germany
| | - Marek Wieczorek
- Miltenyi Biotec B.V. & Co. KG, Friedrich-Ebert-Straße 68, 51429 Bergisch Gladbach, Germany
| | - Martin Listek
- Institute of Biochemistry and Biology, University of Potsdam, Karl-Liebknecht-Straße 24-25, 14476 Potsdam, Germany
| | - Florian Tomszak
- Miltenyi Biotec B.V. & Co. KG, Friedrich-Ebert-Straße 68, 51429 Bergisch Gladbach, Germany
| | - Volker Nölle
- Miltenyi Biotec B.V. & Co. KG, Friedrich-Ebert-Straße 68, 51429 Bergisch Gladbach, Germany
| | - Katja Hanack
- Institute of Biochemistry and Biology, University of Potsdam, Karl-Liebknecht-Straße 24-25, 14476 Potsdam, Germany
| | - Miriam Droste
- Miltenyi Biotec B.V. & Co. KG, Friedrich-Ebert-Straße 68, 51429 Bergisch Gladbach, Germany.
| |
Collapse
|
6
|
Zhu D, Wang Z, Xu Y, Lin J, Qiu M, Liu J, Li X. Novel application of anti‐human Fc nanobody for screening high‐producing CHO cells for monoclonal antibody. Eng Life Sci 2022; 22:608-618. [PMID: 36247827 PMCID: PMC9550735 DOI: 10.1002/elsc.202200028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2022] [Revised: 08/05/2022] [Accepted: 08/09/2022] [Indexed: 11/08/2022] Open
Abstract
Animal‐derived anti‐IgG secondary antibodies are currently employed to stain and screen of human monoclonal antibody(mAb)‐producing cells, but using animal‐derived antibodies may raise the concerns of high cost, complicated operations and biological safety issues in biopharmaceutical manufacturing. Nanobodies(VHHs) are attractive forms of antibodies for their straightforward engineering and expression in both eukaryotic and prokaryotic systems. Using phage‐displayed immune llama VHH library, we identified new anti‐Fc VHHs that could bind to human Fc with high affinity. In GFP fusion format, the anti‐Fc VHH‐GFP generated dramatically stronger FACS signals than AF488 conjugated anti‐IgG antibodies when used for staining mAb‐producing CHO cells. Furthermore, preparative sorting of CHO cells based on anti‐Fc VHH‐GFP staining resulted in the enrichment of cell lines capable of synthesizing mAb at high productivity. This safe and cost‐efficient anti‐Fc VHH‐GFP may optimize the process of generating highly productive cell lines for therapeutic mAb production compared to conventional animal‐derived fluorescent antibodies.
Collapse
Affiliation(s)
- Di Zhu
- Chengdu Medical College Sichuan Province China
| | - Zheng Wang
- Shanghai Bao Pharmaceuticals Co. Ltd. Shanghai China
| | - Yunxia Xu
- Shanghai Bao Pharmaceuticals Co. Ltd. Shanghai China
| | - Jing Lin
- ABLINK Biotech Co. Ltd. Chengdu China
| | - Mei Qiu
- ABLINK Biotech Co. Ltd. Chengdu China
| | - Jianghai Liu
- Chengdu Medical College Sichuan Province China
- ABLINK Biotech Co. Ltd. Chengdu China
| | - Xinlei Li
- Chengdu Medical College Sichuan Province China
| |
Collapse
|
7
|
Park JH, Lee HM, Jin EJ, Lee EJ, Kang YJ, Kim S, Yoo SS, Lee GM, Kim YG. Development of an in vitro screening system for synthetic signal peptide in mammalian cell-based protein production. Appl Microbiol Biotechnol 2022; 106:3571-3582. [PMID: 35581431 DOI: 10.1007/s00253-022-11955-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2022] [Revised: 04/28/2022] [Accepted: 05/03/2022] [Indexed: 11/27/2022]
Abstract
Optimizing appropriate signal peptides in mammalian cell-based protein production is crucial given that most recombinant proteins produced in mammalian cells are thought to be secreted proteins. Until now, most studies on signal peptide in mammalian cells have replaced native signal peptides with well-known heterologous signal peptides and bioinformatics-based signal peptides. In the present study, we successfully established an in vitro screening system for synthetic signal peptide in CHO cells by combining a degenerate codon-based oligonucleotides library, a site-specific integration system, and a FACS-based antibody detection assay. Three new signal peptides were screened using this new screening system, confirming to have structural properties as signal peptides by the SignalP web server, a neural network-based algorithm that quantifies the signal peptide-ness of amino acid sequences. The novel signal peptides selected in this study increased Fc-fusion protein production in CHO cells by increasing specific protein productivity, whereas they did not negatively affect cell growth. Particularly, the SP-#149 clone showed the highest qp, 0.73 ± 0.01 pg/cell/day from day 1 to day 4, representing a 1.47-fold increase over the native signal peptide in a serum-free suspension culture mode. In addition, replacing native signal peptide with the novel signal peptides did not significantly affect sialylated N-glycan formation, N-terminal cleavage pattern, and biological function of Fc-fusion protein produced in CHO cells. The overall results indicate the utility of a novel in vitro screening system for synthetic signal peptide for mammalian cell-based protein production. KEY POINTS: • An in vitro screening system for synthetic signal peptide in mammalian cells was established • This system combined a degenerate codon-based library, site-specific integration, and a FACS-based detection assay • The novel signal peptides selected in this study could increase Fc-fusion protein production in mammalian cells.
Collapse
Affiliation(s)
- Jong-Ho Park
- Department of Biological Sciences, KAIST, 335 Gwahak-ro, Yuseong-gu, Daejeon, Korea
- Biotherapeutics Translational Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), 125 Gwahak-ro, Yuseong-gu, Daejeon, Korea
| | - Hoon-Min Lee
- Biotherapeutics Translational Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), 125 Gwahak-ro, Yuseong-gu, Daejeon, Korea
- Department of Bioprocess Engineering, KRIBB School of Biotechnology, Korea University of Science and Technology (UST), 217 Gajeong-ro, Yuseong-gu, Daejeon, Korea
| | - Eun-Ju Jin
- Biotherapeutics Translational Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), 125 Gwahak-ro, Yuseong-gu, Daejeon, Korea
- Department of Bioprocess Engineering, KRIBB School of Biotechnology, Korea University of Science and Technology (UST), 217 Gajeong-ro, Yuseong-gu, Daejeon, Korea
| | - Eun-Ji Lee
- Biotherapeutics Translational Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), 125 Gwahak-ro, Yuseong-gu, Daejeon, Korea
- Department of Bioprocess Engineering, KRIBB School of Biotechnology, Korea University of Science and Technology (UST), 217 Gajeong-ro, Yuseong-gu, Daejeon, Korea
| | - Yeon-Ju Kang
- Biotherapeutics Translational Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), 125 Gwahak-ro, Yuseong-gu, Daejeon, Korea
- Department of Bioprocess Engineering, KRIBB School of Biotechnology, Korea University of Science and Technology (UST), 217 Gajeong-ro, Yuseong-gu, Daejeon, Korea
| | - Sungkyun Kim
- Choong Ang Vaccine Laboratory Co., Ltd. (CAVAC), 1476-37 Yuseong-daero, Yuseong-gu, Daejeon, Korea
| | - Sung-Sick Yoo
- Choong Ang Vaccine Laboratory Co., Ltd. (CAVAC), 1476-37 Yuseong-daero, Yuseong-gu, Daejeon, Korea
| | - Gyun Min Lee
- Department of Biological Sciences, KAIST, 335 Gwahak-ro, Yuseong-gu, Daejeon, Korea.
| | - Yeon-Gu Kim
- Biotherapeutics Translational Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), 125 Gwahak-ro, Yuseong-gu, Daejeon, Korea.
- Department of Bioprocess Engineering, KRIBB School of Biotechnology, Korea University of Science and Technology (UST), 217 Gajeong-ro, Yuseong-gu, Daejeon, Korea.
| |
Collapse
|
8
|
Peliçário Vargas B, Sari MHM, Ferreira LM. Trastuzumab in breast cancer treatment: the Era of biosimilars. Anticancer Agents Med Chem 2022; 22:2507-2516. [PMID: 35236272 DOI: 10.2174/1871520622666220302114313] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2021] [Revised: 11/24/2021] [Accepted: 12/19/2021] [Indexed: 11/22/2022]
Abstract
BACKGROUND The discovery of trastuzumab as anti-HER2 therapy markedly improved disease control and the survival rates of patients with HER2+ breast cancer. However, as trastuzumab is considered a complex molecule, the cost of production is usually elevated, which significantly affects health budgets and limits the treatment access for patients who live in underdeveloped countries. Recently, trastuzumab production became more accessible and sustainable due to the patents' expiration, allowing biosimilar versions of trastuzumab to be developed. OBJECTIVE Our main goal was to shed more light on the uses of biosimilars in breast cancer treatment, emphasizing trastuzumab. METHOD An integrative review was carried out in the PubMed, Scielo, Web of Science, and SCOPUS databases using the terms "biosimilar," "breast cancer," "monoclonal antibody," and "trastuzumab." The time range included scientific articles published from 2015 to 2021. RESULTS AND DISCUSSION The bibliographic survey showed the complexities in biological medicine manufacturing and how the monoclonal antibody's therapy with trastuzumab improved the patients' life expectancy, revolutionizing HER2+ breast cancer treatment. Nonetheless, despite its benefits, trastuzumab generates certain restrictions, especially from the economic perspective. Trastuzumab biosimilars have high selectivity and rarely cause adverse effects compared to conventional chemotherapy. CONCLUSION This study shows that trastuzumab biosimilars improve patients' accessibility to breast cancer treatment through a safe and effective therapy compared to the drug reference.
Collapse
Affiliation(s)
- Bárbara Peliçário Vargas
- Departamento de Farmácia Industrial, Curso de Farmácia, Centro de Ciências da Saúde, Universidade Federal de Santa Maria, Santa Maria, Brazil
| | | | - Luana Mota Ferreira
- Departamento de Farmácia Industrial, Curso de Farmácia, Centro de Ciências da Saúde, Universidade Federal de Santa Maria, Santa Maria, Brazil;
- Programa de Pós-graduação em Ciências Farmacêuticas, Centro de Ciências da Saúde, Universidade Federal de Santa Maria, Santa Maria, Brazil
| |
Collapse
|
9
|
Tejwani V, Chaudhari M, Rai T, Sharfstein ST. High-throughput and automation advances for accelerating single-cell cloning, monoclonality and early phase clone screening steps in mammalian cell line development for biologics production. Biotechnol Prog 2021; 37:e3208. [PMID: 34478248 DOI: 10.1002/btpr.3208] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2021] [Revised: 08/30/2021] [Accepted: 09/01/2021] [Indexed: 12/13/2022]
Abstract
Mammalian cell line development is a multistep process wherein timelines for developing clonal cells to be used as manufacturing cell lines for biologics production can commonly extend to 9 months when no automation or modern molecular technologies are involved in the workflow. Steps in the cell line development workflow involving single-cell cloning, monoclonality assurance, productivity and stability screening are labor, time and resource intensive when performed manually. Introduction of automation and miniaturization in these steps has reduced the required manual labor, shortened timelines from months to weeks, and decreased the resources needed to develop manufacturing cell lines. This review summarizes the advances, benefits, comparisons and shortcomings of different automation platforms available in the market for rapid isolation of desired clonal cell lines for biologics production.
Collapse
Affiliation(s)
- Vijay Tejwani
- Biotechnology R&D, Clone Development Team, Lupin Limited, Pune, India
| | - Minal Chaudhari
- Biotechnology R&D, Clone Development Team, Lupin Limited, Pune, India
| | - Toyaj Rai
- Biotechnology R&D, Clone Development Team, Lupin Limited, Pune, India
| | - Susan T Sharfstein
- College of Nanoscale Science and Engineering, SUNY Polytechnic Institute, Albany, New York, USA
| |
Collapse
|
10
|
Meyer KV, Siller IG, Schellenberg J, Gonzalez Salcedo A, Solle D, Matuszczyk J, Scheper T, Bahnemann J. Monitoring cell productivity for the production of recombinant proteins by flow cytometry: An effective application using the cold capture assay. Eng Life Sci 2021; 21:288-293. [PMID: 33976601 PMCID: PMC8092981 DOI: 10.1002/elsc.202000049] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2020] [Revised: 11/19/2020] [Accepted: 11/29/2020] [Indexed: 11/07/2022] Open
Abstract
Due to the increasing economic and social relevance of biotherapeutics, their production processes are continually being reconsidered and reoptimized in an effort to secure higher product concentrations and qualities. Monitoring the productivity of cultured cells is therefore a critically important part of the cultivation process. Traditionally, this is achieved by determining the overall product titer by high performance liquid chromatography (HPLC), and then calculating the specific cell productivity based on this titer and an associated viable cell density. Unfortunately, this process is typically time-consuming and laborious. In this study, the productivity of Chinese Hamster Ovary (CHO) cells expressing a monoclonal antibody was analyzed over the course of the cultivation process. In addition to calculating the specific cell productivity based on the traditional product titer determined by HPLC analysis, culture productivity of single cells was also analyzed via flow cytometry using a cold capture assay. The cold capture assay is a cell surface labelling technique described by Brezinsky et al., which allows for the visualization of a product on the surface of the producing cell. The cell productivity results obtained via HPLC and the results of cold capture assay remained in great accordance over the whole cultivation process. Accordingly, our study demonstrates that the cold capture assay offers an interesting, comparatively time-effective, and potentially cheaper alternative for monitoring the productivity of a cell culture.
Collapse
Affiliation(s)
- Katharina V. Meyer
- Institute of Technical ChemistryLeibniz University HannoverHannoverGermany
| | - Ina G. Siller
- Institute of Technical ChemistryLeibniz University HannoverHannoverGermany
| | - Jana Schellenberg
- Institute of Technical ChemistryLeibniz University HannoverHannoverGermany
| | | | - Dörte Solle
- Institute of Technical ChemistryLeibniz University HannoverHannoverGermany
| | | | - Thomas Scheper
- Institute of Technical ChemistryLeibniz University HannoverHannoverGermany
| | - Janina Bahnemann
- Institute of Technical ChemistryLeibniz University HannoverHannoverGermany
| |
Collapse
|
11
|
Lin MW, Shen CC, Lin YJ, Chou MY, Pham NN, Chang YH, Chang CW, Hwu JR, Nguyen MTT, Hu YC. Enhancing the yield and activity of defucosylated antibody produced by CHO-K1 cells using Cas13d-mediated multiplex gene targeting. J Taiwan Inst Chem Eng 2021. [DOI: 10.1016/j.jtice.2021.03.040] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
|
12
|
Aebischer-Gumy C, Moretti P, Ollier R, Ries Fecourt C, Rousseau F, Bertschinger M. SPLICELECT™: an adaptable cell surface display technology based on alternative splicing allowing the qualitative and quantitative prediction of secreted product at a single-cell level. MAbs 2021; 12:1709333. [PMID: 31955651 PMCID: PMC6973322 DOI: 10.1080/19420862.2019.1709333] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
We describe a mammalian expression construct (SPLICELECT™) that allows the redirection of a proportion of a secreted protein onto the cell surface using alternative splicing: whereas the majority of the RNA is spliced into a transcript encoding a secreted protein, a weak splice donor site yields a secondary transcript encoding, in addition, a C-terminal transmembrane domain. The different sequence elements can be modified in order to modulate the level of cell surface display and of secretion in an independent manner. In this work, we demonstrated that the cell surface display of stable cell lines is correlated with the level of the secreted protein of interest, but also with the level of heterodimerization in the case of a bispecific antibody. It was also shown that this construct may be useful for rapid screening of multiple antibody candidates in binding assays following transient transfection. Thus, the correlation of product quantity and quality of the secreted and of membrane-displayed product in combination with the flexibility of the construct with regards to cell surface display/secretion levels make SPLICELECT™ a valuable tool with many potential applications, not limited to industrial cell line development or antibody engineering.
Collapse
Affiliation(s)
- Christel Aebischer-Gumy
- Cell Sciences, Ichnos Sciences SA (formerly Glenmark Pharmaceuticals SA), La Chaux-de-Fonds, Switzerland
| | - Pierre Moretti
- Cell Sciences, Ichnos Sciences SA (formerly Glenmark Pharmaceuticals SA), La Chaux-de-Fonds, Switzerland
| | - Romain Ollier
- Antibody Engineering, Ichnos Sciences SA (formerly Glenmark Pharmaceuticals SA), La Chaux-de-Fonds, Switzerland
| | - Christelle Ries Fecourt
- Antibody Engineering, Ichnos Sciences SA (formerly Glenmark Pharmaceuticals SA), La Chaux-de-Fonds, Switzerland
| | - François Rousseau
- Antibody Engineering, Ichnos Sciences SA (formerly Glenmark Pharmaceuticals SA), La Chaux-de-Fonds, Switzerland
| | - Martin Bertschinger
- Cell Sciences, Ichnos Sciences SA (formerly Glenmark Pharmaceuticals SA), La Chaux-de-Fonds, Switzerland
| |
Collapse
|
13
|
Bakhtiari H, Palizban AA, Khanahmad H, Mofid MR. An innovative cell selection approach in developing human cells overexpressing aspartyl/asparaginyl β-hydroxylase. Res Pharm Sci 2020; 15:291-299. [PMID: 33088329 PMCID: PMC7540811 DOI: 10.4103/1735-5362.288436] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2020] [Revised: 05/22/2020] [Accepted: 05/26/2020] [Indexed: 11/09/2022] Open
Abstract
Background and purpose: Aspartyl/asparaginyl β-hydroxylase (ASPH) is abundantly expressed in malignant neoplastic cells. The establishment of a human cell line overexpressing ASPH could provide the native-like recombinant protein needed for developing theranostic probes. In the process of transfection, the obtained cells normally contain a range of cells expressing the different levels of the target of interest. In this paper, we report on our simple innovative approach in the selection of best-transfected cells with the highest expression of ASPH using subclone selection, quantitative real-time polymerase chain reaction, and gradual increment of hygromycin concentration. Experimental approach: To achieve this goal, human embryonic kidney (HEK 293T) cells were transfected with an ASPH-bearing pcDNA3.1/Hygro(+) vector. During antibiotic selection, single accumulations of the resistant cells were separately cultured and the ASPH mRNA levels of each flask were evaluated. The best subclones were treated with a gradually increasing amount of hygromycin. The ASPH protein expression of the obtained cells was finally evaluated using flow cytometry and immunocytochemistry. Findings / Results: The results showed that different selected subclones expressed different levels of ASPH. Furthermore, the gradual increment of hygromycin (up to 400mg/mL) improved the expression of ASPH. The best relative fold change in mRNA levels was 57.59 ± 4.11. Approximately 90.2% of HEKASPH cells overexpressed ASPH on their surface. Conclusion and implications: The experiments indicated that we have successfully constructed and evaluated a recombinant human cell line overexpressing ASPH on the surface. Moreover, our innovative selection approach provided an effective procedure for enriching highly expressing recombinant cells.
Collapse
Affiliation(s)
- Hadi Bakhtiari
- Department of Clinical Biochemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, I.R. Iran
| | - Abbas Ali Palizban
- Department of Clinical Biochemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, I.R. Iran
| | - Hossein Khanahmad
- Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, I.R. Iran
| | - Mohammad Reza Mofid
- Department of Clinical Biochemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, I.R. Iran
| |
Collapse
|
14
|
Srirangan K, Loignon M, Durocher Y. The use of site-specific recombination and cassette exchange technologies for monoclonal antibody production in Chinese Hamster ovary cells: retrospective analysis and future directions. Crit Rev Biotechnol 2020; 40:833-851. [DOI: 10.1080/07388551.2020.1768043] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Affiliation(s)
- Kajan Srirangan
- Mammalian Cell Expression, Human Health Therapeutics Research Centre, National Research Council Canada, Montréal, Québec, Canada
| | - Martin Loignon
- Mammalian Cell Expression, Human Health Therapeutics Research Centre, National Research Council Canada, Montréal, Québec, Canada
| | - Yves Durocher
- Mammalian Cell Expression, Human Health Therapeutics Research Centre, National Research Council Canada, Montréal, Québec, Canada
- Département de biochimie et médecine moléculaire, Université de Montréal, Montréal, Québec, Canada
| |
Collapse
|
15
|
Pourcel L, Buron F, Garcia F, Delaloix MS, Le Fourn V, Girod PA, Mermod N. Transient vitamin B5 starving improves mammalian cell homeostasis and protein production. Metab Eng 2020; 60:77-86. [PMID: 32247827 DOI: 10.1016/j.ymben.2020.03.008] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2019] [Revised: 01/23/2020] [Accepted: 03/22/2020] [Indexed: 12/13/2022]
Abstract
Maintaining a metabolic steady state is essential for an organism's fitness and survival when confronted with environmental stress, and metabolic imbalance can be reversed by exposing the organism to fasting. Here, we attempted to apply this physiological principle to mammalian cell cultures to improve cellular fitness and consequently their ability to express recombinant proteins. We showed that transient vitamin B5 deprivation, an essential cofactor of central cellular metabolism, can quickly and irreversibly affect mammalian cell growth and division. A selection method was designed that relies on mammalian cell dependence on vitamin B5 for energy production, using the co-expression of the B5 transporter SLC5A6 and a gene of interest. We demonstrated that vitamin B5 selection persistently activates peroxisome proliferator-activated receptors (PPAR), a family of transcription factors involved in energy homeostasis, thereby altering lipid metabolism, improving cell fitness and therapeutic protein production. Thus, stable PPAR activation may constitute a cellular memory of past deprivation state, providing increased resistance to further potential fasting events. In other words, our results imply that cultured cells, once exposed to metabolic starvation, may display an improved metabolic fitness as compared to non-exposed cells, allowing increased resistance to cellular stress.
Collapse
Affiliation(s)
- Lucille Pourcel
- Center for Biotechnology and Department of Fundamental Microbiology, University of Lausanne, UNIL-EPFL, Lausanne, Switzerland.
| | - Flavien Buron
- Center for Biotechnology and Department of Fundamental Microbiology, University of Lausanne, UNIL-EPFL, Lausanne, Switzerland
| | - Fanny Garcia
- Center for Biotechnology and Department of Fundamental Microbiology, University of Lausanne, UNIL-EPFL, Lausanne, Switzerland
| | - Margaux-Sarah Delaloix
- Center for Biotechnology and Department of Fundamental Microbiology, University of Lausanne, UNIL-EPFL, Lausanne, Switzerland
| | | | | | - Nicolas Mermod
- Center for Biotechnology and Department of Fundamental Microbiology, University of Lausanne, UNIL-EPFL, Lausanne, Switzerland
| |
Collapse
|
16
|
Pourcel L, Buron F, Arib G, Le Fourn V, Regamey A, Bodenmann I, Girod P, Mermod N. Influence of cytoskeleton organization on recombinant protein expression by CHO cells. Biotechnol Bioeng 2020; 117:1117-1126. [PMID: 31956990 PMCID: PMC7079171 DOI: 10.1002/bit.27277] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2019] [Revised: 12/27/2019] [Accepted: 01/11/2020] [Indexed: 12/12/2022]
Abstract
In this study, we assessed the importance of cytoskeleton organization in the mammalian cells used to produce therapeutic proteins. Two cytoskeletal genes, Actin alpha cardiac muscle 1 (ACTC1) and a guanosine triphosphate GTPase-activating protein (TAGAP), were found to be upregulated in highly productive therapeutic protein-expressing Chinese hamster ovary (CHO) cells selected by the deprivation of vitamin B5. We report here that the overexpression of the ACTC1 protein was able to improve significantly recombinant therapeutic production, as well as to decrease the levels of toxic lactate metabolic by-products. ACTC1 overexpression was accompanied by altered as well as decreased polymerized actin, which was associated with high protein production by CHO cell cultured in suspension. We suggest that the depolymerization of actin and the possible modulation of integrin signaling, as well as changes in basal metabolism, may be driving the increase of protein secretion by CHO cells.
Collapse
Affiliation(s)
- Lucille Pourcel
- Department of Fundamental Microbiology, Institute of BiotechnologyUniversity of LausanneLausanneSwitzerland
| | - Flavien Buron
- Department of Fundamental Microbiology, Institute of BiotechnologyUniversity of LausanneLausanneSwitzerland
| | | | | | | | | | | | - Nicolas Mermod
- Department of Fundamental Microbiology, Institute of BiotechnologyUniversity of LausanneLausanneSwitzerland
| |
Collapse
|
17
|
Enabling HEK293 cells for antibiotic-free media bioprocessing through CRISPR/Cas9 gene editing. Biochem Eng J 2019. [DOI: 10.1016/j.bej.2019.107299] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|
18
|
Zika virus-like particles (VLPs): Stable cell lines and continuous perfusion processes as a new potential vaccine manufacturing platform. Vaccine 2019; 37:6970-6977. [DOI: 10.1016/j.vaccine.2019.05.064] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2018] [Revised: 04/11/2019] [Accepted: 05/22/2019] [Indexed: 12/16/2022]
|
19
|
Hahm YH, Lee JY, Ahn YH. Investigation of Site-Specific Differences in Glycan Microheterogeneity by N-Glycopeptide Mapping of VEGFR-IgG Fusion Protein. Molecules 2019; 24:molecules24213924. [PMID: 31671706 PMCID: PMC6864772 DOI: 10.3390/molecules24213924] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2019] [Revised: 10/24/2019] [Accepted: 10/29/2019] [Indexed: 12/13/2022] Open
Abstract
A biosimilar fusion protein VEGFR-IgG consisting of vascular endothelial growth factor receptors 1 and 2 (VEGFR-1, VEGFR-2) and the Fc portion of human IgG1 was prepared for this study. The prepared fusion protein was expected to possess a total of five N-linked glycosylation sites: two sites in the VEGFR-1 region, two sites in the VEGFR-2 region, and one site in the human IgG Fc region. For site-specific glycan analysis, the fusion protein was hydrolyzed with trypsin, and the resulting tryptic digests were analyzed by liquid chromatography-electrospray ionization tandem mass spectrometry (LC-ESI MS/MS). The expected N-linked glycosylation sites were successfully identified and site-specific glycopeptide mapping was completed by Integrated GlycoProteome Analyzer (I-GPA) for the resulting raw tandem mass data. Finally, it was clearly confirmed that N-linked glycans for each glycosylation site showed significantly different patterns in microheterogeneity, which may indicate certain functions for each glycosylation site in the protein. Based on the mapping results, the unique features in glycan microheterogeneity for the five glycosylation sites of VEGFR-IgG fusion protein were compared site-specifically and further discussed to understand the functional meaning of each glycosylation pattern.
Collapse
Affiliation(s)
| | - Ju Yeon Lee
- Korea Basic Science Institute, Biomedical Omics Research Group, Cheongju 28119, Korea.
| | - Yeong Hee Ahn
- Department of Biomedical Science, Cheongju University, Cheongju 28160, Korea.
| |
Collapse
|
20
|
Chakrabarti L, Zhuang L, Roy G, Bowen MA, Dall’Acqua WF, Hawley‐Nelson P, Marelli M. Amber suppression coupled with inducible surface display identifies cells with high recombinant protein productivity. Biotechnol Bioeng 2019; 116:793-804. [PMID: 30536645 PMCID: PMC6590230 DOI: 10.1002/bit.26892] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2018] [Accepted: 12/06/2018] [Indexed: 12/19/2022]
Abstract
Cell line development (CLD) for biotherapeutics is a time- and resource-intensive process requiring the isolation and screening of large numbers of clones to identify high producers. Novel methods aimed at enhancing cell line screening efficiency using markers predictive of productivity early in the CLD process are needed to reliably generate high-yielding cell lines. To enable efficient and selective isolation of antibody expressing Chinese hamster ovary cells by fluorescence-activated cell sorting, we developed a strategy for the expression of antibodies containing a switchable membrane-associated domain to anchor an antibody to the membrane of the expressing cell. The switchable nature of the membrane domain is governed by the function of an orthogonal aminoacyl transfer RNA synthetase/tRNApyl pair, which directs a nonnatural amino acid (nnAA) to an amber codon encoded between the antibody and the membrane anchor. The process is "switchable" in response to nnAA in the medium, enabling a rapid transition between the surface display and secretion. We demonstrate that the level of cell surface display correlates with productivity and provides a method for enriching phenotypically stable high-producer cells. The strategy provides a means for selecting high-producing cells with potential applications to multiple biotherapeutic protein formats.
Collapse
Affiliation(s)
- Lina Chakrabarti
- Cell Culture and Fermentation Science, MedImmuneGaithersburgMaryland
| | - Li Zhuang
- Antibody Discovery and Protein Engineering, MedImmuneGaithersburgMaryland
| | - Gargi Roy
- Antibody Discovery and Protein Engineering, MedImmuneGaithersburgMaryland
| | - Michael A. Bowen
- Antibody Discovery and Protein Engineering, MedImmuneGaithersburgMaryland
| | | | - Pam Hawley‐Nelson
- Cell Culture and Fermentation Science, MedImmuneGaithersburgMaryland
| | - Marcello Marelli
- Antibody Discovery and Protein Engineering, MedImmuneGaithersburgMaryland
| |
Collapse
|
21
|
Moore B, Sanford R, Zhang A. Case study: The characterization and implementation of dielectric spectroscopy (biocapacitance) for process control in a commercial GMP CHO manufacturing process. Biotechnol Prog 2019; 35:e2782. [DOI: 10.1002/btpr.2782] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2018] [Revised: 12/20/2018] [Accepted: 01/28/2019] [Indexed: 01/22/2023]
Affiliation(s)
- Brandon Moore
- Cell Culture Development; Biogen, Research Triangle Park; North Carolina
| | - Ryan Sanford
- Cell Culture Development; Biogen, Research Triangle Park; North Carolina
| | - An Zhang
- Cell Culture Development; Biogen, Research Triangle Park; North Carolina
| |
Collapse
|
22
|
Chakrabarti L, Mathew A, Li L, Han S, Klover J, Albanetti T, Hawley-Nelson P. Mitochondrial membrane potential identifies cells with high recombinant protein productivity. J Immunol Methods 2019; 464:31-39. [DOI: 10.1016/j.jim.2018.10.007] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2018] [Revised: 10/04/2018] [Accepted: 10/16/2018] [Indexed: 12/11/2022]
|
23
|
Stuible M, van Lier F, Croughan MS, Durocher Y. Beyond preclinical research: production of CHO-derived biotherapeutics for toxicology and early-phase trials by transient gene expression or stable pools. Curr Opin Chem Eng 2018. [DOI: 10.1016/j.coche.2018.09.010] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
24
|
Wang B, Albanetti T, Miro-Quesada G, Flack L, Li L, Klover J, Burson K, Evans K, Ivory W, Bowen M, Schoner R, Hawley-Nelson P. High-throughput screening of antibody-expressing CHO clones using an automated shaken deep-well system. Biotechnol Prog 2018; 34:1460-1471. [PMID: 30298994 PMCID: PMC6587815 DOI: 10.1002/btpr.2721] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2018] [Revised: 08/30/2018] [Accepted: 09/20/2018] [Indexed: 12/15/2022]
Abstract
Biopharmaceutical protein manufacturing requires the highest producing cell lines to satisfy current multiple grams per liter requirements. Screening more clones increases the probability of identifying the high producers within the pool of available transfectant candidate cell lines. For the predominant industry mammalian host cell line, Chinese hamster ovary (CHO), traditional static‐batch culture screening does not correlate with the suspension fed‐batch culture used in manufacturing, and thus has little predictive utility. Small scale fed‐batch screens in suspension culture correlate better with bioreactor processes but a limited number of clones can be screened manually. Scaled‐down systems, such as shaken deep well plates, combined with automated liquid handling, offer a way for a limited number of scientists to screen many clones. A statistical analysis determined that 384 is the optimal number of clones to screen, with a 99% probability that six clones in the 95th percentile for productivity are included in the screen. To screen 384 clones efficiently by the predictive method of suspension fed‐batch, the authors developed a shaken deep‐well plate culturing platform, with an automated liquid handling system integrating cell counting and protein titering instruments. Critical factors allowing deep‐well suspension culture to correlate with shake flask culture were agitation speed and culture volume. Using our automated system, one scientist can screen five times more clones than by manual fed‐batch shake‐flask or shaken culture tube screens and can identify cell lines for some therapeutic protein projects with production levels greater than 6 g/L. © 2018 American Institute of Chemical Engineers Biotechnol. Prog., 34:1460–1471, 2018
Collapse
Affiliation(s)
- Benjamin Wang
- Cell Culture and Fermentation Sciences, MedImmune, Gaithersburg, Maryland, 20878
| | - Thomas Albanetti
- Cell Culture and Fermentation Sciences, MedImmune, Gaithersburg, Maryland, 20878
| | | | - Layla Flack
- Cell Culture and Fermentation Sciences, MedImmune, Gaithersburg, Maryland, 20878
| | - Lina Li
- Cell Culture and Fermentation Sciences, MedImmune, Gaithersburg, Maryland, 20878
| | - Judith Klover
- Cell Culture and Fermentation Sciences, MedImmune, Gaithersburg, Maryland, 20878
| | - Kerri Burson
- Cell Culture and Fermentation Sciences, MedImmune, Gaithersburg, Maryland, 20878
| | - Krista Evans
- Cell Culture and Fermentation Sciences, MedImmune, Gaithersburg, Maryland, 20878
| | - William Ivory
- Analytical Biochemistry, MedImmune, Gaithersburg, Maryland, 20878
| | - Michael Bowen
- Cell Culture and Fermentation Sciences, MedImmune, Gaithersburg, Maryland, 20878
| | - Ronald Schoner
- Cell Culture and Fermentation Sciences, MedImmune, Gaithersburg, Maryland, 20878
| | - Pamela Hawley-Nelson
- Cell Culture and Fermentation Sciences, MedImmune, Gaithersburg, Maryland, 20878
| |
Collapse
|
25
|
Dhami N, Trivedi DK, Goodacre R, Mainwaring D, Humphreys DP. Mitochondrial aconitase is a key regulator of energy production for growth and protein expression in Chinese hamster ovary cells. Metabolomics 2018; 14:136. [PMID: 30830403 DOI: 10.1007/s11306-018-1430-0] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/05/2018] [Accepted: 09/21/2018] [Indexed: 12/19/2022]
Abstract
INTRODUCTION Mammalian cells like Chinese hamster ovary (CHO) cells are routinely used for production of recombinant therapeutic proteins. Cells require a continuous supply of energy and nutrients to sustain high cell densities whilst expressing high titres of recombinant proteins. Cultured mammalian cells are primarily dependent on glucose and glutamine metabolism for energy production. OBJECTIVES The TCA cycle is the main source of energy production and its continuous flow is essential for cell survival. Modulated regulation of TCA cycle can affect ATP production and influence CHO cell productivity. METHODS To determine the key metabolic reactions of the cycle associated with cell growth in CHO cells, we transiently silenced each gene of the TCA cycle using RNAi. RESULTS Silencing of at least four TCA cycle genes was detrimental to CHO cell growth. With an exception of mitochondrial aconitase (or Aco2), all other genes were associated with ATP production reactions of the TCA cycle and their resulting substrates can be supplied by other anaplerotic and cataplerotic reactions. This study is the first of its kind to have established key role of aconitase gene in CHO cells. We further investigated the temporal effects of aconitase silencing on energy production, CHO cell metabolism, oxidative stress and recombinant protein production. CONCLUSION Transient silencing of mitochondrial aconitase inhibited cell growth, reduced ATP production, increased production of reactive oxygen species and reduced cell specific productivity of a recombinant CHO cell line by at least twofold.
Collapse
Affiliation(s)
- Neha Dhami
- Protein Sciences, UCB, 216 Bath Road, Slough, Berkshire, SL1 3WE, UK.
| | - Drupad K Trivedi
- Manchester Institute of Biotechnology and School of Chemistry, University of Manchester, 131 Princess Street, Manchester, M1 7DN, UK
| | - Royston Goodacre
- Manchester Institute of Biotechnology and School of Chemistry, University of Manchester, 131 Princess Street, Manchester, M1 7DN, UK
| | - David Mainwaring
- Protein Sciences, UCB, 216 Bath Road, Slough, Berkshire, SL1 3WE, UK
- Pall Europe Limited, 5 Harbourgate Business Park, Southampton Road, Portsmouth, Hampshire, PO6 4BQ, UK
| | - David P Humphreys
- Protein Sciences, UCB, 216 Bath Road, Slough, Berkshire, SL1 3WE, UK
| |
Collapse
|
26
|
Hunter M, Yuan P, Vavilala D, Fox M. Optimization of Protein Expression in Mammalian Cells. ACTA ACUST UNITED AC 2018; 95:e77. [DOI: 10.1002/cpps.77] [Citation(s) in RCA: 64] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
27
|
Comparative Glycopeptide Analysis for Protein Glycosylation by Liquid Chromatography and Tandem Mass Spectrometry: Variation in Glycosylation Patterns of Site-Directed Mutagenized Glycoprotein. Int J Anal Chem 2018; 2018:8605021. [PMID: 30245723 PMCID: PMC6139207 DOI: 10.1155/2018/8605021] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2018] [Revised: 06/29/2018] [Accepted: 07/31/2018] [Indexed: 01/16/2023] Open
Abstract
Glycosylation is one of the most important posttranslational modifications for proteins, including therapeutic antibodies, and greatly influences protein physiochemical properties. In this study, glycopeptide mapping of a reference and biosimilar recombinant antibodies (rAbs) was performed using liquid chromatography-electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS) and an automated Glycoproteome Analyzer (GPA) algorithm. The tandem mass analyses for the reference and biosimilar samples indicate that this approach proves to be highly efficient in reproducing consistent analytical results and discovering the implications of different rAb production methods on glycosylation patterns. Furthermore, the comparative analysis of a mutagenized rAb glycoprotein proved that a single amino acid mutation in the Fc portion of the antibody molecule caused increased variations in glycosylation patterns. These variations were also detected by the mass spectrometry method efficiently. This mapping method, focusing on precise glycopeptide identification and comparison for the identified glycoforms, can be useful in differentiating aberrant glycosylation in biosimilar rAb products.
Collapse
|
28
|
Pristovšek N, Hansen HG, Sergeeva D, Borth N, Lee GM, Andersen MR, Kildegaard HF. Using Titer and Titer Normalized to Confluence Are Complementary Strategies for Obtaining Chinese Hamster Ovary Cell Lines with High Volumetric Productivity of Etanercept. Biotechnol J 2018; 13:e1700216. [DOI: 10.1002/biot.201700216] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2017] [Revised: 12/15/2017] [Indexed: 12/29/2022]
Affiliation(s)
- Nuša Pristovšek
- The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark; Kemitorvet, Building 220 2800 Kgs. Lyngby Denmark
| | - Henning Gram Hansen
- The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark; Kemitorvet, Building 220 2800 Kgs. Lyngby Denmark
| | - Daria Sergeeva
- The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark; Kemitorvet, Building 220 2800 Kgs. Lyngby Denmark
| | - Nicole Borth
- Department of Biotechnology, University of Natural Resources and Life Sciences; Muthgasse 18 1190 Vienna Austria
- Austrian Centre of Industrial Biotechnology (ACIB); Muthgasse 11 1190 Vienna Austria
| | - Gyun Min Lee
- The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark; Kemitorvet, Building 220 2800 Kgs. Lyngby Denmark
- Department of Biological Sciences, KAIST; 291 Daehak-ro, Yuseong-gu Daejeon 305-701 Republic of Korea
| | - Mikael Rørdam Andersen
- Department of Biotechnology and Biomedicine, Technical University of Denmark; Søltofts Plads, Building 221 2800 Kgs. Lyngby Denmark
| | - Helene Faustrup Kildegaard
- The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark; Kemitorvet, Building 220 2800 Kgs. Lyngby Denmark
| |
Collapse
|
29
|
Turaj AH, Hussain K, Cox KL, Rose-Zerilli MJJ, Testa J, Dahal LN, Chan HTC, James S, Field VL, Carter MJ, Kim HJ, West JJ, Thomas LJ, He LZ, Keler T, Johnson PWM, Al-Shamkhani A, Thirdborough SM, Beers SA, Cragg MS, Glennie MJ, Lim SH. Antibody Tumor Targeting Is Enhanced by CD27 Agonists through Myeloid Recruitment. Cancer Cell 2017; 32:777-791.e6. [PMID: 29198913 PMCID: PMC5734932 DOI: 10.1016/j.ccell.2017.11.001] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/11/2017] [Revised: 08/28/2017] [Accepted: 10/27/2017] [Indexed: 12/12/2022]
Abstract
Monoclonal antibodies (mAbs) can destroy tumors by recruiting effectors such as myeloid cells, or targeting immunomodulatory receptors to promote cytotoxic T cell responses. Here, we examined the therapeutic potential of combining a direct tumor-targeting mAb, anti-CD20, with an extended panel of immunomodulatory mAbs. Only the anti-CD27/CD20 combination provided cures. This was apparent in multiple lymphoma models, including huCD27 transgenic mice using the anti-huCD27, varlilumab. Detailed mechanistic analysis using single-cell RNA sequencing demonstrated that anti-CD27 stimulated CD8+ T and natural killer cells to release myeloid chemo-attractants and interferon gamma, to elicit myeloid infiltration and macrophage activation. This study demonstrates the therapeutic advantage of using an immunomodulatory mAb to regulate lymphoid cells, which then recruit and activate myeloid cells for enhanced killing of mAb-opsonized tumors.
Collapse
Affiliation(s)
- Anna H Turaj
- Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK; Cancer Research UK Centre, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK
| | - Khiyam Hussain
- Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK
| | - Kerry L Cox
- Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK
| | - Matthew J J Rose-Zerilli
- Cancer Research UK Centre, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK
| | - James Testa
- Celldex Therapeutics, Inc., Hampton, NJ 08827, USA
| | - Lekh N Dahal
- Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK
| | - H T Claude Chan
- Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK
| | - Sonya James
- Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK
| | - Vikki L Field
- Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK
| | - Matthew J Carter
- Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK
| | - Hyung J Kim
- Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK
| | - Jonathan J West
- Institute for Life Sciences, Faculty of Medicine, University of Southampton, Southampton SO17 1BJ, UK
| | | | - Li-Zhen He
- Celldex Therapeutics, Inc., Hampton, NJ 08827, USA
| | - Tibor Keler
- Celldex Therapeutics, Inc., Hampton, NJ 08827, USA
| | - Peter W M Johnson
- Cancer Research UK Centre, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK
| | - Aymen Al-Shamkhani
- Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK
| | - Stephen M Thirdborough
- Cancer Research UK Centre, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK
| | - Stephen A Beers
- Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK; Cancer Research UK Centre, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK
| | - Mark S Cragg
- Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK; Cancer Research UK Centre, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK; Institute for Life Sciences, Faculty of Medicine, University of Southampton, Southampton SO17 1BJ, UK
| | - Martin J Glennie
- Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK
| | - Sean H Lim
- Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK; Cancer Research UK Centre, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK.
| |
Collapse
|
30
|
Sequential screening by ClonePix FL and intracellular staining facilitate isolation of high producer cell lines for monoclonal antibody manufacturing. J Immunol Methods 2017; 451:100-110. [DOI: 10.1016/j.jim.2017.08.012] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2017] [Revised: 08/09/2017] [Accepted: 08/29/2017] [Indexed: 01/14/2023]
|
31
|
Dahal LN, Dou L, Hussain K, Liu R, Earley A, Cox KL, Murinello S, Tracy I, Forconi F, Steele AJ, Duriez PJ, Gomez-Nicola D, Teeling JL, Glennie MJ, Cragg MS, Beers SA. STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy. Cancer Res 2017; 77:3619-3631. [PMID: 28512240 PMCID: PMC5500176 DOI: 10.1158/0008-5472.can-16-2784] [Citation(s) in RCA: 50] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2016] [Revised: 02/24/2017] [Accepted: 04/19/2017] [Indexed: 12/13/2022]
Abstract
Tumors routinely attract and co-opt macrophages to promote their growth, angiogenesis, and metastasis. Macrophages are also the key effector cell for mAb therapies. Here we report that the tumor microenvironment creates an immunosuppressive signature on tumor-associated macrophages (TAM), which favors expression of inhibitory rather than activating Fcγ receptors (FcγR), thereby limiting the efficacy of mAb immunotherapy. We assessed a panel of TLR and STING agonists (a) for their ability to reprogram macrophages to a state optimal for mAb immunotherapy. Both STINGa and TLRa induced cytokine release, modulated FcγR expression, and augmented mAb-mediated tumor cell phagocytosis in vitro However, only STINGa reversed the suppressive FcγR profile in vivo, providing strong adjuvant effects to anti-CD20 mAb in murine models of lymphoma. Potent adjuvants like STINGa, which can improve FcγR activatory:inhibitory (A:I) ratios on TAM, are appealing candidates to reprogram TAM and curb tumor-mediated immunosuppression, thereby empowering mAb efficacy. Cancer Res; 77(13); 3619-31. ©2017 AACR.
Collapse
Affiliation(s)
- Lekh N Dahal
- Antibody & Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United Kingdom
| | - Lang Dou
- Antibody & Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United Kingdom
| | - Khiyam Hussain
- Antibody & Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United Kingdom
| | - Rena Liu
- Antibody & Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United Kingdom
| | - Alexander Earley
- Antibody & Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United Kingdom
| | - Kerry L Cox
- Antibody & Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United Kingdom
| | - Salome Murinello
- Centre for Biological Sciences, University of Southampton, Southampton General Hospital, Southampton, United Kingdom
| | - Ian Tracy
- Cancer Sciences Unit, Cancer Research UK and NIHR Experimental Cancer Medicine Centres, University of Southampton, Southampton General Hospital, Southampton, United Kingdom
| | - Francesco Forconi
- Cancer Sciences Unit, Cancer Research UK and NIHR Experimental Cancer Medicine Centres, University of Southampton, Southampton General Hospital, Southampton, United Kingdom
| | - Andrew J Steele
- Cancer Sciences Unit, Cancer Research UK and NIHR Experimental Cancer Medicine Centres, University of Southampton, Southampton General Hospital, Southampton, United Kingdom
| | - Patrick J Duriez
- Cancer Sciences Unit, Cancer Research UK and NIHR Experimental Cancer Medicine Centres, University of Southampton, Southampton General Hospital, Southampton, United Kingdom
| | - Diego Gomez-Nicola
- Centre for Biological Sciences, University of Southampton, Southampton General Hospital, Southampton, United Kingdom
| | - Jessica L Teeling
- Centre for Biological Sciences, University of Southampton, Southampton General Hospital, Southampton, United Kingdom
| | - Martin J Glennie
- Antibody & Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United Kingdom
| | - Mark S Cragg
- Antibody & Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United Kingdom.
| | - Stephen A Beers
- Antibody & Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United Kingdom.
| |
Collapse
|
32
|
Droz X, Harraghy N, Lançon E, Le Fourn V, Calabrese D, Colombet T, Liechti P, Rida A, Girod PA, Mermod N. Automated microfluidic sorting of mammalian cells labeled with magnetic microparticles for those that efficiently express and secrete a protein of interest. Biotechnol Bioeng 2017; 114:1791-1802. [DOI: 10.1002/bit.26270] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2016] [Revised: 01/05/2017] [Accepted: 02/15/2017] [Indexed: 12/28/2022]
Affiliation(s)
- Xuan Droz
- Department of Fundamental Microbiology, Institute of Biotechnology, University of Lausanne; Center for Biotechnology UNIL-EPFL; Lausanne Switzerland
| | - Niamh Harraghy
- Department of Fundamental Microbiology, Institute of Biotechnology, University of Lausanne; Center for Biotechnology UNIL-EPFL; Lausanne Switzerland
| | - Etienne Lançon
- Department of Fundamental Microbiology, Institute of Biotechnology, University of Lausanne; Center for Biotechnology UNIL-EPFL; Lausanne Switzerland
| | | | | | | | | | | | | | - Nicolas Mermod
- Department of Fundamental Microbiology, Institute of Biotechnology, University of Lausanne; Center for Biotechnology UNIL-EPFL; Lausanne Switzerland
| |
Collapse
|
33
|
Kent JA, Bommaraju TV, Barnicki SD, Kyung YS, Zhang GG. Industrial Production of Therapeutic Proteins: Cell Lines, Cell Culture, and Purification. HANDBOOK OF INDUSTRIAL CHEMISTRY AND BIOTECHNOLOGY 2017. [PMCID: PMC7121293 DOI: 10.1007/978-3-319-52287-6_29] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/02/2022]
Abstract
A central pillar of the biotechnology and pharmaceutical industries continues to be the development of biological drug products manufactured from engineered mammalian cell lines. Since the hugely successful launch of human tissue plasminogen activator in 1987 and erythropoietin in 1988, the biopharmaceutical market has grown immensely. In 2014, biotherapeutics made up a significant portion of global drug sales as 7 of the top 10 and 21 of top 50 selling pharmaceuticals in the world were biologics with over US$100 billion in global sales (Table 1, [1]).
Collapse
|
34
|
Dippong M, Carl P, Lenz C, Schenk JA, Hoffmann K, Schwaar T, Schneider RJ, Kuhne M. Hapten-Specific Single-Cell Selection of Hybridoma Clones by Fluorescence-Activated Cell Sorting for the Generation of Monoclonal Antibodies. Anal Chem 2017; 89:4007-4012. [DOI: 10.1021/acs.analchem.6b04569] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Affiliation(s)
- Martin Dippong
- Bundesanstalt für Materialforschung und -prüfung (BAM), Richard-Willstätter-Str.
11, 12489 Berlin, Germany
- University of Potsdam, Institute for Biochemistry and
Biology, Karl-Liebknecht-Str.
24-25, 14476 Potsdam, Germany
- Fraunhofer Institute for Cell Therapy and Immunology (IZI), Branch Bioanalytics and Bioprocesses Potsdam-Golm, Am Mühlenberg 13, 14476 Potsdam, Germany
| | - Peter Carl
- Bundesanstalt für Materialforschung und -prüfung (BAM), Richard-Willstätter-Str.
11, 12489 Berlin, Germany
- Humboldt-Universität zu Berlin, Department of Chemistry, Brook-Taylor-Str. 2, 12489 Berlin, Germany
| | - Christine Lenz
- UP Transfer GmbH, Am Neuen
Palais 10, 14469 Potsdam, Germany
- Hybrotec GmbH, Am Mühlenberg
11, 14476 Potsdam-Golm, Germany
| | - Jörg A. Schenk
- UP Transfer GmbH, Am Neuen
Palais 10, 14469 Potsdam, Germany
- Hybrotec GmbH, Am Mühlenberg
11, 14476 Potsdam-Golm, Germany
| | - Katrin Hoffmann
- Bundesanstalt für Materialforschung und -prüfung (BAM), Richard-Willstätter-Str.
11, 12489 Berlin, Germany
| | - Timm Schwaar
- Bundesanstalt für Materialforschung und -prüfung (BAM), Richard-Willstätter-Str.
11, 12489 Berlin, Germany
- Humboldt-Universität zu Berlin, Department of Chemistry, Brook-Taylor-Str. 2, 12489 Berlin, Germany
| | - Rudolf J. Schneider
- Bundesanstalt für Materialforschung und -prüfung (BAM), Richard-Willstätter-Str.
11, 12489 Berlin, Germany
| | - Maren Kuhne
- Bundesanstalt für Materialforschung und -prüfung (BAM), Richard-Willstätter-Str.
11, 12489 Berlin, Germany
| |
Collapse
|
35
|
Poitevin Y, Pontini G, Fischer N, Kosco-Vilbois M, Elson G. Magnetic sorting of membrane associated IgG for phenotype-based selection of stable antibody producing cells. J Immunol Methods 2017; 444:1-6. [PMID: 28189705 DOI: 10.1016/j.jim.2017.02.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2016] [Revised: 02/07/2017] [Accepted: 02/07/2017] [Indexed: 12/11/2022]
Abstract
To establish a simple and widely accessible technique for rapidly selecting high producing Chinese hamster ovary (CHO) cells engineered to express a monoclonal antibody (mAb), we have exploited the transient display of recombinant protein on their cell surface. In combination with magnetic bead-based methods, we demonstrate the ability to select for cells of high productivity in the absence of any metabolic-based selection method. This technique is sufficient to obtain genetically stable engineered CHO cells via a single step of cell subcloning and yields sought-after stable, high IgG producing clonal cell lines. This technique may also be applied to other types of cells as well as polyclonal Ab cell pools.
Collapse
Affiliation(s)
- Y Poitevin
- Novimmune SA, 14 chemin des Aulx 1228 Plan-Les-Ouates, Switzerland.
| | - G Pontini
- Novimmune SA, 14 chemin des Aulx 1228 Plan-Les-Ouates, Switzerland
| | - N Fischer
- Novimmune SA, 14 chemin des Aulx 1228 Plan-Les-Ouates, Switzerland
| | - M Kosco-Vilbois
- Novimmune SA, 14 chemin des Aulx 1228 Plan-Les-Ouates, Switzerland
| | - G Elson
- Novimmune SA, 14 chemin des Aulx 1228 Plan-Les-Ouates, Switzerland
| |
Collapse
|
36
|
Gallagher C, Kelly PS. Selection of High-Producing Clones Using FACS for CHO Cell Line Development. Methods Mol Biol 2017; 1603:143-152. [PMID: 28493128 DOI: 10.1007/978-1-4939-6972-2_9] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
Cell line development aims to generate and select clones with desirable characteristics. One of the most important parameters for biopharmaceutical cell selection is cell-specific productivity (Qp) or the quantity of product produced per cell per day. Fluorescence-activated cell sorting (FACS) is a powerful, high-throughput technique that facilitates multiparametric characterization and isolation of individual cell clones from heterogeneous populations. Here, we describe a FACS-based method for section of high-producing CHO cell clones.
Collapse
Affiliation(s)
- Clair Gallagher
- National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland.
| | - Paul S Kelly
- National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland
| |
Collapse
|
37
|
Priola JJ, Calzadilla N, Baumann M, Borth N, Tate CG, Betenbaugh MJ. High-throughput screening and selection of mammalian cells for enhanced protein production. Biotechnol J 2016; 11:853-65. [DOI: 10.1002/biot.201500579] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2015] [Revised: 02/09/2016] [Accepted: 05/17/2016] [Indexed: 01/05/2023]
Affiliation(s)
- Joseph J. Priola
- Department of Chemical and Biomolecular Engineering; Johns Hopkins University; Baltimore MD USA
| | - Nathan Calzadilla
- Department of Chemical and Biomolecular Engineering; Johns Hopkins University; Baltimore MD USA
| | | | - Nicole Borth
- Department of Biotechnology; Universität für Bodenkultur; Vienna Austria
| | | | - Michael J. Betenbaugh
- Department of Chemical and Biomolecular Engineering; Johns Hopkins University; Baltimore MD USA
| |
Collapse
|
38
|
Lang S, Drewello D, Wichter J, Nommay A, Wilms B, Knopf HP, Jostock T. Surface display vectors for selective detection and isolation of high level antibody producing cells. Biotechnol Bioeng 2016; 113:2386-93. [DOI: 10.1002/bit.26000] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2015] [Revised: 03/30/2016] [Accepted: 04/28/2016] [Indexed: 12/20/2022]
Affiliation(s)
- Sabine Lang
- Integrated Biologics Profiling; Novartis Pharma AG; Postfach CH-4002, Basel Switzerland
| | - Delia Drewello
- Integrated Biologics Profiling; Novartis Pharma AG; Postfach CH-4002, Basel Switzerland
| | - Johannes Wichter
- GBW/H, White Biotechnology Research-Microbiology; BASF; Ludwigshafen Germany
| | - Audrey Nommay
- Integrated Biologics Profiling; Novartis Pharma AG; Postfach CH-4002, Basel Switzerland
| | - Burkhard Wilms
- Integrated Biologics Profiling; Novartis Pharma AG; Postfach CH-4002, Basel Switzerland
| | - Hans-Peter Knopf
- Integrated Biologics Profiling; Novartis Pharma AG; Postfach CH-4002, Basel Switzerland
| | - Thomas Jostock
- Integrated Biologics Profiling; Novartis Pharma AG; Postfach CH-4002, Basel Switzerland
| |
Collapse
|
39
|
Use of Human Hybridoma Technology To Isolate Human Monoclonal Antibodies. Microbiol Spectr 2016; 3:AID-0027-2014. [PMID: 26104564 DOI: 10.1128/microbiolspec.aid-0027-2014] [Citation(s) in RCA: 51] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The human hybridoma technique offers an important approach for isolation of human monoclonal antibodies. A diversity of approaches can be used with varying success. Recent technical advances in expanding the starting number of human antigen-specific B cells, improving fusion efficiency, and isolating new myeloma partners and new cell cloning methods have enabled the development of protocols that make the isolation of human monoclonal antibodies from blood samples feasible. Undoubtedly, additional innovations that could improve efficiency are possible.
Collapse
|
40
|
Misaghi S, Shaw D, Louie S, Nava A, Simmons L, Snedecor B, Poon C, Paw JS, Gilmour-Appling L, Cupp JE. Slashing the timelines: Opting to generate high-titer clonal lines faster via viability-based single cell sorting. Biotechnol Prog 2015; 32:198-207. [DOI: 10.1002/btpr.2204] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2015] [Revised: 10/28/2015] [Indexed: 11/07/2022]
Affiliation(s)
- Shahram Misaghi
- Dept. of Early Stage Cell Culture; Genentech, Inc; 1 DNA Way South San Francisco CA 94080
| | - David Shaw
- Dept. of Early Stage Cell Culture; Genentech, Inc; 1 DNA Way South San Francisco CA 94080
| | - Salina Louie
- Dept. of Early Stage Cell Culture; Genentech, Inc; 1 DNA Way South San Francisco CA 94080
| | - Adrian Nava
- Dept. of Early Stage Cell Culture; Genentech, Inc; 1 DNA Way South San Francisco CA 94080
| | - Laura Simmons
- Dept. of Early Stage Cell Culture; Genentech, Inc; 1 DNA Way South San Francisco CA 94080
| | - Brad Snedecor
- Dept. of Early Stage Cell Culture; Genentech, Inc; 1 DNA Way South San Francisco CA 94080
| | - Chungkee Poon
- Dept. of Immunology; Genentech, Inc; 1 DNA Way South San Francisco CA 94080
| | - Jonathan S. Paw
- Dept. of Immunology; Genentech, Inc; 1 DNA Way South San Francisco CA 94080
| | | | - James E. Cupp
- Dept. of Immunology; Genentech, Inc; 1 DNA Way South San Francisco CA 94080
| |
Collapse
|
41
|
Optimization of cell line development in the GS-CHO expression system using a high-throughput, single cell-based clone selection system. J Biosci Bioeng 2015; 120:323-9. [DOI: 10.1016/j.jbiosc.2015.01.002] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2014] [Revised: 12/22/2014] [Accepted: 01/06/2015] [Indexed: 11/19/2022]
|
42
|
Harraghy N, Calabrese D, Fisch I, Girod PA, LeFourn V, Regamey A, Mermod N. Epigenetic regulatory elements: Recent advances in understanding their mode of action and use for recombinant protein production in mammalian cells. Biotechnol J 2015; 10:967-78. [DOI: 10.1002/biot.201400649] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2015] [Revised: 04/20/2015] [Accepted: 05/20/2015] [Indexed: 12/18/2022]
|
43
|
Okumura T, Masuda K, Watanabe K, Miyadai K, Nonaka K, Yabuta M, Omasa T. Efficient enrichment of high-producing recombinant Chinese hamster ovary cells for monoclonal antibody by flow cytometry. J Biosci Bioeng 2015; 120:340-6. [PMID: 25683450 DOI: 10.1016/j.jbiosc.2015.01.007] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2014] [Revised: 01/05/2015] [Accepted: 01/07/2015] [Indexed: 10/24/2022]
Abstract
To screen a high-producing recombinant Chinese hamster ovary (CHO) cell from transfected cells is generally laborious and time-consuming. We developed an efficient enrichment strategy for high-producing cell screening using flow cytometry (FCM). A stable pool that had possibly shown a huge variety of monoclonal antibody (mAb) expression levels was prepared by transfection of an expression vector for mAb production to a CHO cell. To enrich high-producing cells derived from a stable pool stained with a fluorescent-labeled antibody that binds to mAb presented on the cell surface, we set the cell size and intracellular density gates based on forward scatter (FSC) and side scatter (SSC), and collected the brightest 5% of fluorescein isothiocyanate (FITC)-positive cells from each group by FCM. The final product concentration in a fed-batch culture of cells sorted without FSC and SSC gates was 1.2-1.3-times higher than that of unsorted cells, whereas that of cells gated by FSC and SSC was 3.4-4.7-fold higher than unsorted cells. Surprisingly, the fraction with the highest final product concentration indicated the smallest value of FSC and SSC, and the middle value of fluorescence intensity among all fractionated cells. Our results showed that our new screening strategy by FCM based on FSC and SSC gates could achieve an efficient enrichment of high-producing cells with the smallest value of FSC and SSC.
Collapse
Affiliation(s)
- Takeshi Okumura
- R&D Division, Daiichi Sankyo Co., Ltd., Gunma 370-0503, Japan; Institute of Technology and Science, The University of Tokushima, 2-1 Minamijosanjima-cho, Tokushima 770-8506, Japan.
| | - Kenji Masuda
- R&D Division, Daiichi Sankyo Co., Ltd., Gunma 370-0503, Japan
| | | | - Kenji Miyadai
- R&D Division, Daiichi Sankyo Co., Ltd., Gunma 370-0503, Japan
| | - Koichi Nonaka
- R&D Division, Daiichi Sankyo Co., Ltd., Gunma 370-0503, Japan
| | - Masayuki Yabuta
- R&D Division, Daiichi Sankyo Co., Ltd., Gunma 370-0503, Japan
| | - Takeshi Omasa
- Institute of Technology and Science, The University of Tokushima, 2-1 Minamijosanjima-cho, Tokushima 770-8506, Japan
| |
Collapse
|
44
|
Kao CH, Wang JY, Chuang KH, Chuang CH, Cheng TC, Hsieh YC, Tseng YL, Chen BM, Roffler SR, Cheng TL. One-step mixing with humanized anti-mPEG bispecific antibody enhances tumor accumulation and therapeutic efficacy of mPEGylated nanoparticles. Biomaterials 2014; 35:9930-9940. [DOI: 10.1016/j.biomaterials.2014.08.032] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2014] [Accepted: 08/20/2014] [Indexed: 12/11/2022]
|
45
|
Almo SC, Love JD. Better and faster: improvements and optimization for mammalian recombinant protein production. Curr Opin Struct Biol 2014; 26:39-43. [PMID: 24721463 DOI: 10.1016/j.sbi.2014.03.006] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2014] [Revised: 03/04/2014] [Accepted: 03/10/2014] [Indexed: 11/18/2022]
Abstract
Thanks to numerous technological advances, the production of recombinant proteins in mammalian cell lines has become an increasingly routine task that is no longer viewed as a heroic enterprise. While production in prokaryotic or lower eukaryotic systems may be more rapid and economical, the advantages of producing large amounts of protein that closely resembles the native form is often advantageous and may be essential for the realization of functionally active material for biological studies or biopharmaceuticals. The correct folding, processing and post-translational modifications conferred by expression in a mammalian cell is relevant to all classes of proteins, including cytoplasmic, secreted or integral membrane proteins. Therefore considerable efforts have focused on the development of growth media, cell lines, transformation methods and selection techniques that enable the production of grams of functional protein in weeks, rather than months. This review will focus on a plethora of methods that are broadly applicable to the high yield production of any class of protein (cytoplasmic, secreted or integral membrane) from mammalian cells.
Collapse
Affiliation(s)
- Steven C Almo
- Department of Biochemistry, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, United States
| | - James D Love
- Department of Biochemistry, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, United States.
| |
Collapse
|
46
|
Hou JJC, Hughes BS, Smede M, Leung KM, Levine K, Rigby S, Gray PP, Munro TP. High-throughput ClonePix FL analysis of mAb-expressing clones using the UCOE expression system. N Biotechnol 2014; 31:214-20. [PMID: 24518824 DOI: 10.1016/j.nbt.2014.02.002] [Citation(s) in RCA: 45] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2013] [Revised: 01/21/2014] [Accepted: 02/02/2014] [Indexed: 10/25/2022]
Abstract
Therapeutic recombinant monoclonal antibodies (mAbs) are commonly produced by high-expressing, clonal, mammalian cells. Creation of these clones for manufacturing remains heavily reliant on stringent selection and gene amplification, which in turn can lead to genetic instability, variable expression, product heterogeneity and prolonged development timelines. Inclusion of cis-acting ubiquitous chromatin opening elements (UCOE™) in mammalian expression vectors has been shown to improve productivity and facilitate high-level gene expression irrespective of the chromosomal integration site without lengthy gene amplification protocols. In this study we have used high-throughput robotic clone selection in combination with UCOE™ containing expression vectors to develop a rapid, streamlined approach for early-stage cell line development and isolation of high-expressing clones for mAb production using Chinese hamster ovary (CHO) cells. Our results demonstrate that it is possible to go from transfection to stable clones in only 4 weeks, while achieving specific productivities exceeding 20 pg/cell/day. Furthermore, we have used this approach to quickly screen several process-crucial parameters including IgG subtype, enhancer-promoter combination and UCOE™ length. The use of UCOE™-containing vectors in combination with automated robotic selection provides a rapid method for the selection of stable, high-expressing clones.
Collapse
Affiliation(s)
- Jeff Jia Cheng Hou
- The University of Queensland, Australian Institute for Bioengineering and Nanotechnology, Brisbane, QLD 4072, Australia.
| | - Ben S Hughes
- The University of Queensland, Australian Institute for Bioengineering and Nanotechnology, Brisbane, QLD 4072, Australia
| | - Matthew Smede
- The University of Queensland, Australian Institute for Bioengineering and Nanotechnology, Brisbane, QLD 4072, Australia
| | - Kar Man Leung
- The University of Queensland, Australian Institute for Bioengineering and Nanotechnology, Brisbane, QLD 4072, Australia
| | - Kara Levine
- Pharm Chemical Solution (PCS), EMD Millipore, 2 Gill Street, Woburn, MA 01801, USA
| | - Susan Rigby
- Pharm Chemical Solution (PCS), EMD Millipore, 2 Gill Street, Woburn, MA 01801, USA
| | - Peter P Gray
- The University of Queensland, Australian Institute for Bioengineering and Nanotechnology, Brisbane, QLD 4072, Australia
| | - Trent P Munro
- The University of Queensland, Australian Institute for Bioengineering and Nanotechnology, Brisbane, QLD 4072, Australia
| |
Collapse
|
47
|
Vidigal J, Dias MM, Fernandes F, Patrone M, Bispo C, Andrade C, Gardner R, Carrondo MJ, Alves PM, Teixeira AP. A cell sorting protocol for selecting high-producing sub-populations of Sf9 and High Five™ cells. J Biotechnol 2013; 168:436-9. [DOI: 10.1016/j.jbiotec.2013.10.020] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2013] [Revised: 10/10/2013] [Accepted: 10/15/2013] [Indexed: 10/26/2022]
|
48
|
The use of glutamine synthetase as a selection marker: recent advances in Chinese hamster ovary cell line generation processes. ACTA ACUST UNITED AC 2013. [DOI: 10.4155/pbp.13.56] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
49
|
Harada G, Matsumoto SE, Yamashita M, Fujii K, Shirahata S, Katakura Y. In vitro immunization of Epstein-Barr virus-immortalized B cells augments antigen-specific antibody production. Cytotechnology 2013; 65:979-83. [PMID: 23949581 PMCID: PMC3853636 DOI: 10.1007/s10616-013-9596-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2013] [Accepted: 06/03/2013] [Indexed: 10/26/2022] Open
Abstract
The current method for in vitro immunization (IVI) uses several antigens including toxins, food allergens, pathogenic bacteria, and self-antigen-derived peptides that induce an antigen-specific immune response in peripheral blood mononuclear cells (PBMCs). This protocol, however, requires donor blood collection and preparation of PBMCs before every IVI. In the present study, we aimed to design a more efficient system utilizing B cells immortalized with Epstein-Barr virus (EBV-B) as host cells for IVI to make antigen-specific antibodies. Results showed that previously antigen-sensitized, EBV-B cells exposed to the antigen along with IL-6, CpG oligonucleotides, and CD40 ligand signal produced antigen-specific antibodies. These results provide evidence for a novel and easy method to expand memory-type B cells and produce antigen-specific antibodies.
Collapse
Affiliation(s)
- Gakuro Harada
- />Graduate School of Systems Life Sciences, Kyushu University, 6-10-1 Hakozaki, Higashi-ku, Fukuoka, 812-8581 Japan
| | - Shin-ei Matsumoto
- />Faculty of Agriculture, Kyushu University, 6-10-1 Hakozaki, Higashi-ku, Fukuoka, 812-8581 Japan
| | - Makiko Yamashita
- />Faculty of Agriculture, Kyushu University, 6-10-1 Hakozaki, Higashi-ku, Fukuoka, 812-8581 Japan
| | - Kaoru Fujii
- />Graduate School of Systems Life Sciences, Kyushu University, 6-10-1 Hakozaki, Higashi-ku, Fukuoka, 812-8581 Japan
| | - Sanetaka Shirahata
- />Graduate School of Systems Life Sciences, Kyushu University, 6-10-1 Hakozaki, Higashi-ku, Fukuoka, 812-8581 Japan
- />Faculty of Agriculture, Kyushu University, 6-10-1 Hakozaki, Higashi-ku, Fukuoka, 812-8581 Japan
| | - Yoshinori Katakura
- />Graduate School of Systems Life Sciences, Kyushu University, 6-10-1 Hakozaki, Higashi-ku, Fukuoka, 812-8581 Japan
- />Faculty of Agriculture, Kyushu University, 6-10-1 Hakozaki, Higashi-ku, Fukuoka, 812-8581 Japan
| |
Collapse
|
50
|
Williams EL, Tutt AL, Beers SA, French RR, Chan CHT, Cox KL, Roghanian A, Penfold CA, Butts CL, Boross P, Verbeek JS, Cragg MS, Glennie MJ. Immunotherapy Targeting Inhibitory Fcγ Receptor IIB (CD32b) in the Mouse Is Limited by Monoclonal Antibody Consumption and Receptor Internalization. THE JOURNAL OF IMMUNOLOGY 2013; 191:4130-40. [DOI: 10.4049/jimmunol.1301430] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|